Abstract
The 5 alpha-reductase inhibitor, finasteride, provides a logical medical treatment for benign prostatic hyperplasia (BPH). However, the effects of chronic finasteride treatment on prostatic androgen levels, 5 alpha-reductase activity and tissue prostatic specific antigen (PSA) have not been studied. We have examined prostate tissue androgen concentrations and 5 alpha-reductase activity of the gland in men with BPH treated with the drug for 3 months.
| Original language | English |
|---|---|
| Pages (from-to) | 137-44 |
| Number of pages | 8 |
| Journal | Clinical Endocrinology |
| Volume | 46 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 1997 |
Keywords
- 5-alpha reductase inhibitors
- aged
- androgens
- androstenedione
- dihydrotestosterone
- double-blind method
- finasteride
- humans
- prostate
- prostate-specific antigen
- prostatic hyperplasia
- testosterone